← FDA DRUG APPROVALS

FDA ANDA · ANDA205227

TEMOZOLOMIDE

Sponsor: EXTROVIS

APPLICATION
ANDA205227
TYPE
ANDA
ORIGINAL APPROVAL
2016-06-29
LATEST ACTION
2016-06-29
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 180MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 100MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 5MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 250MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 140MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 20MG · CAPSULE · ORAL

Approval history

2016-06-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →